Remoxipride hydrochloride is a new selective dopamine D2-antagonist for the treatment
of schizophrenia and other psychoses where thought disorders are prominent symptoms.
Efficacy appears to be similar to that of haloperidol, with reportedly significantly less
extrapyramidal side-effects.
